Investing.com - Quest Diagnostics (NYSE: DGX) reported third quarter EPS of $2.22, $0.03 better than the analyst estimate of $2.19. Revenue for the quarter came in at $2.3B versus the consensus estimate of $2.27B.
Guidance
Quest Diagnostics sees FY 2023 EPS of $8.65-$8.75 versus the analyst consensus of $8.71.
Quest Diagnostics sees FY 2023 revenue of $9.19B-$9.24B versus the analyst consensus of $9.18B.
Quest Diagnostics's stock price closed at $121.45. It is down -9.61% in the last 3 months and down -15.69% in the last 12 months.
Quest Diagnostics saw 1 positive EPS revisions and 11 negative EPS revisions in the last 90 days. See Quest Diagnostics's stock price’s past reactions to earnings here.
According to InvestingPro, Quest Diagnostics's Financial Health score is "great performance".
Check out Quest Diagnostics's recent earnings performance, and Quest Diagnostics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar